Senses Disorder TRIZ Cases

Arylated camphene compounds selectively stimulate CB2 receptors, avoiding psychoactive side effects from CB1 activation.

Hollow three-dimensional retinal tissue units enable minimally invasive implantation of differentiated pigment epithelium cells.

Segmented microspheres with flexible polymer shells maintain steady protein delivery over 60 days, reducing intraocular injection frequency.

Standardized saffron crocin with curcumin treats degenerative eye disorders by reducing oxidative stress without invasive procedures.

Benzooxazol-2-one derivatives modify chemical structures to inhibit hormone-sensitive and endothelial lipases, reducing free fatty acids and blood sugar levels.

Lubricin eye drops stabilize the tear film refractive index to correct higher order aberrations and reduce halos.

Bivalent diazo bicyclic Smac mimetics inhibit IAPs to sensitize resistant cancer cells.

Stem cell-derived RPE cells slow geographic atrophy progression by stabilizing retinal layers, addressing insufficient visual function restoration in dry AMD.

Segmented copolymers form a cross-linked network that sustains prostaglandin release, eliminating surgical removal after treatment.

Quinone compounds normalize ATP and coenzyme Q levels, resolving inadequate symptom management in mitochondrial diseases.

Cyclic polypeptides inhibit C5 cleavage via disulfide bridges, reducing self-cell lysis while maintaining high binding specificity.

Eliminating beta-casein A1 from milk products lowers dipeptidyl peptidase IV activity and improves insulin sensitivity to manage hyperglycemia.

Selective PKCβII inhibition via substituted pyrrolo[3,4-c]pyrazoles addresses inadequate disease management in diabetes and cancer.

Allogeneic colony-forming somatic cells reduce manufacturing complexity by eliminating patient-specific production delays.

Conjugating anti-VEGF-A antibodies to phosphorylcholine polymers extends half-life and reduces administration frequency for diabetic retinopathy treatment.

Segmented heterocycle-piperidine derivatives bind p75 NTR receptors, addressing the lack of effective compounds for neurodegenerative disease treatment.

Lrg1 antagonists block TGFβ-mediated vascular remodelling, resolving VEGF therapy trade-offs.

Syringaresinol selectively activates SIRT1 expression to restore mitochondrial function and improve metabolic disorders.

Pre-incubating adeno-associated virus with hyaluronic acid prevents capsid aggregation, improving retinal transduction efficiency and reducing required doses.

A tetrahydroisoquinoline derivative maintains embryonic stem cells in an undifferentiated state without feeder cells.

Targeted compounds inhibit store-operated calcium channels to control intracellular calcium influx and reduce pathological cytokine release.

An miRNA modulator inhibits miR-152 or miR-195 to regulate sFlt-1 expression levels.

Manf therapy addresses drug resistance and low penetration of acyclovir by restoring corneal sensitivity and tear secretion.

Oral wafer bypasses first-pass metabolism to increase plasma levels and reduce side effects.

A brimonidine tartrate ophthalmic composition uses hydroxypropyl methylcellulose to enhance drug permeability.

Segmented heterocyclic structures achieve selective PI3K inhibition, reducing tumor proliferation while sparing other kinase activities.

Extracting crude lutein esters from marigold flowers and applying twice drying simplifies production costs while maintaining capsule stability.

Modified TGF-beta oligonucleotides inhibit fibrotic scarring to maintain bleb size and lower intraocular pressure after trabeculectomy.

Synthetic saccharides isolate protective epitopes to eliminate non-protective antibodies and toxicities.

Heparin-binding peptide conjugates deliver active agents to cartilage and neuronal tissues, reducing systemic circulation and off-target effects.

Combining povidone-iodine with anti-inflammatory agents creates a stable ophthalmic composition that treats ocular infections.

Anti-Sp35 antibodies block endogenous Sp35 function to resolve growth cone collapse and promote axon regeneration in neurological injuries.

Removing chelating agents eliminates astringent discomfort while boric acid buffers maintain physiological pH for effective corneal defect treatment.

AAV vector expressing CD47 augments SIRPα signaling, delaying cone death and preserving visual function across diverse genetic mutations.

An adeno-associated viral construct delivers matrix metalloproteinase-3 to corneal endothelial cells.

Sp35 antagonists block inhibitory binding to ErbB2 receptors, promoting oligodendrocyte differentiation and myelination.

Modifying the AAV capsid peptide sequence increases infection efficiency in hair cells, reducing hearing loss and dizziness.

Merging proparacaine hydrochloride and povidone-iodine into one formulation reduces procedure time and patient discomfort during intraocular injections.

Substituted heteroaryl derivatives modulate the opioid receptor system to provide analgesic activity.

Ethyne derivatives inhibit acetyl-CoA carboxylase enzymes, addressing limited metabolic disorder treatments.

A lacrimal implant system delivers sustained-release anti-glaucoma agents directly into the tear drainage pathway.

Engineered AAV44.9 vector overcomes low tropism to deliver genes into cochlear and vestibular tissues, enabling long-term expression for treating hearing loss.

High-concentration replacement enzymes diffuse through cerebrospinal fluid to reach deep brain tissues.

Crystalline solvate salt of tryptophan derivative incorporates alkyl alcohol molecules to address stability deterioration in aqueous solutions.

Extracellular vesicles expressing rPAX6 and rCOL7A1 restore limbal stem cell niches, preventing rejection risks while improving corneal transparency.

Screening cell populations using COL11A1 and COL16A1 gene expression ratios to SDHA ensures low aggregability for safe intravenous administration.

Novel macrolide compounds selectively inhibit phosphodiesterase 4 through a fused five-membered lactone ring structure.